The U.S. District Court for the Northern District of Mississippi has entered a consent decree prohibiting Delta Pharma from manufacturing or distributing compounded drugs until they comply with the Federal Food, Drug, and Cosmetic Act and FDA regulations, the Food and Drug Administration announced Friday. The company is registered as an outsourcing facility under Section 503B of the Act. "That legislation envisioned an important role for outsourcing facilities to help supply providers with compounded medicines, but it also required that these firms meet good manufacturing practice requirements,” said FDA Commissioner Scott Gottlieb, M.D. “When we find outsourcing facilities that continue to violate the law by not adhering to these manufacturing requirements, and put patients at risk, we’re going to hold them accountable under the law. At the same time, we’re also pursuing new policy steps to help make it more feasible for compounders to meet the requirements of becoming an outsourcing facility.”

Related News Articles

Headline
The AHA today voiced support for the Recovering Excessive Funds for Unused and Needless Drugs Act (S. 551), legislation that would incentivize manufacturers to…
Headline
The House Ways and Means Committee today approved the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act (H.R. 2113), AHA-supported…
Headline
Idaho Gov. Brad Little this week signed legislation adding work requirements to the state’s plan to expand Medicaid coverage to low-income adults.
Headline
Sen. Bernie Sanders, I-Vt., and 14 of his Democratic colleagues today introduced the Medicare for All Act of 2019, legislation that would create a national…
Headline
The Food and Drug Administration plans to revise its 2016 draft compounding guidance for hospital and health system pharmacies.
Headline
Reps. Earl Blumenauer, D-Ore., and Markwayne Mullin, R-Okla., yesterday reintroduced  the Overdose Prevention and Patient Safety Act (H.R. 2062), AHA-supported…